Stocktoria
Candel Therapeutics, Inc. CADL
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-27
Candel Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $125,000 | $125,000 | $125,000 |
| R&D expense | $30.5M | $19.3M | $24.5M | $20.8M | $15.2M | $8.8M |
| Operating income | -$48.3M | -$33.4M | -$38.4M | -$34.7M | -$25.7M | -$13.8M |
| Interest expense | $2.1M | $2.1M | -$2.6M | $1.7M | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$38.2M | -$55.2M | -$37.9M | -$18.8M | -$36.1M | -$17.7M |
| EPS (diluted) | $-0.72 | $-1.74 | $-1.31 | $-0.65 | $-1.91 | — |
| Operating cash flow | -$38.3M | -$27.0M | -$34.2M | -$31.4M | -$22.2M | -$9.1M |
| Free cash flow | -$38.9M | -$27.0M | -$34.7M | -$32.7M | -$24.1M | -$10.5M |
| Cash & equivalents | $119.7M | $102.7M | $35.4M | $70.1M | $82.6M | $35.1M |
| Total assets | $125.2M | $106.9M | $41.2M | $77.7M | $89.2M | $38.3M |
| Total liabilities | $73.3M | $40.5M | $28.5M | $30.0M | $25.1M | $12.8M |
| Shareholders' equity | $51.9M | $66.3M | $12.7M | $47.7M | $64.1M | -$23.6M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | +0.0% | +0.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.